Lofexidine hydrochloride
Brand names: BritLofex
Lofexidine hydrochloride is a centrally acting alpha-2 adrenergic agonist used to manage the symptoms of opioid withdrawal during detoxification.
Adult dose
Dose adjustments
§2.3, Table 2 verbatim — Moderate impairment (estimated GFR 30 to 89.9 mL/min/1.73 m2): '2 tablets 4 times daily (1.44 mg per day)'. Severe impairment, End-Stage Renal Disease, or on dialysis (estimated GFR < 30): '1 tablet 4 times daily (0.72 mg per day)'. Also: 'Lofexidine tablets may be administered without regard to the timing of dialysis.' §5.1 additionally advises avoiding use in patients with chronic renal failure.
§2.2, Table 1 verbatim — Mild impairment (Child-Pugh 5 to 6): '3 tablets 4 times daily (2.16 mg per day)'. Moderate impairment (Child-Pugh 7 to 9): '2 tablets 4 times daily (1.44 mg per day)'. Severe impairment (Child-Pugh > 9): '1 tablet 4 times daily (0.72 mg per day)'. §5.2 additionally recommends ECG monitoring in patients with hepatic impairment.
Dose independently re-sourced from US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.
Contraindications
- None — §4 CONTRAINDICATIONS reads in full: 'None.' (US label). The entries below are §5 avoidance statements, NOT labelled contraindications.
- Not a contraindication but an avoidance (§5.1): 'Avoid use in patients with severe coronary insufficiency, recent myocardial infarction, cerebrovascular disease, or chronic renal failure, as well as in patients with marked bradycardia.'
- Not a contraindication but an avoidance (§5.2): 'Avoid use in patients with congenital long QT syndrome.'
Side effects
- §6 most common adverse reactions (incidence ≥ 10% and notably more frequent than placebo): orthostatic hypotension, bradycardia, hypotension, dizziness, somnolence, sedation, and dry mouth
- Hypotension, bradycardia and syncope (§5.1) — 'May cause a decrease in blood pressure, a decrease in pulse, and syncope.'
- QT prolongation (§5.2) — 'Lofexidine prolong the QT interval.'
- Central nervous system depression (§5.3) — potentiates the CNS depressant effects of benzodiazepines, and may potentiate those of alcohol, barbiturates and other sedating drugs
- Increased risk of opioid overdose after opioid discontinuation (§5.4) — 'Patients who complete opioid discontinuation are at an increased risk of fatal overdose' (§5 truncated at the source-fetch limit)
- Discontinuation symptoms (§5.5) — lofexidine withdrawal symptoms if stopped abruptly rather than tapered over 2 to 4 days
Monitoring
- §5.1: 'Monitor vital signs before dosing and advise patients on how to minimize the risk of these cardiovascular effects and manage symptoms, should they occur. Monitor symptoms related to bradycardia and orthostasis.'
- §5.1 outpatient use: 'When using in outpatients, ensure that patients are capable of self-monitoring for signs and symptoms.'
- §5.2 ECG: 'Monitor ECG in patients with electrolyte abnormalities, congestive heart failure, bradyarrhythmias, hepatic or renal impairment, or in patients taking other medicinal products that lead to QT prolongation.'
- §7.1 with methadone: 'Lofexidine and methadone both prolong the QT interval. ECG monitoring is recommended in patients receiving methadone and lofexidine concomitantly.'
- §7.4 with CYP2D6 inhibitors: 'Monitor for symptoms of orthostasis and bradycardia with concomitant use of a CYP2D6 inhibitor' (concomitant paroxetine increased plasma lofexidine levels)
Clinical monograph
How it works
By stimulating central alpha-2 adrenoceptors it reduces sympathetic (noradrenergic) overactivity, easing the autonomic symptoms associated with opioid withdrawal.
Prescribing in practice
- It can cause hypotension, bradycardia and QT-interval prolongation, so blood pressure and pulse should be monitored and it should be used with caution in cardiovascular disease.
- Doses should be reduced gradually at the end of treatment, as abrupt withdrawal may cause rebound hypertension.
- Use with caution in patients with renal impairment or a history of QT prolongation.
Monitoring
Monitor blood pressure and heart rate during treatment and on withdrawal, with attention to symptoms of hypotension and bradycardia.
Counselling the patient
- Explain that the medicine relieves withdrawal symptoms but is not an opioid substitute.
- Rise slowly from sitting or lying because of the risk of dizziness.
- Report fainting, slow heartbeat or palpitations.
Evidence & guidelines
Lofexidine is an established option for managing opioid withdrawal symptoms and is supported by NICE guidance on drug misuse and detoxification.
Reference: NICE CG52; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185